Atherosclerosis Drug Discovery

1. Front Matter

   Pages i-x

   PDF

2. Primate Models

   1. Front Matter

      Pages 1-1

      PDF

   2. A Model for Therapeutic Interventions on Established Coronary Atherosclerosis in a Nonhuman Primate

      • M. R. Malinow, Phyllis McLaughlin, Lynne Papworth, H. K. Naito, Lena Lewis, W. P. McNulty

      Pages 3-31

   3. The Nonhuman Primates as Models for Studying Human Atherosclerosis: Studies on the Chimpanzee, the Baboon and the Rhesus Macacus

      • V. Blaton, H. Peeters

      Pages 33-64

   4. Phylogenetic Variability of Serum Lipids and Lipoproteins in Nonhuman Primates Fed Diets with Different Contents of Dietary Cholesterol

      • S. R. Srinivasan, C. C. Smith, B. Radhakrishnamurthy, R. H. Wolf, G. S. Berenson

      Pages 65-75

   5. The Baboon in Atherosclerosis Research: Comparison with Other Species and Use in Testing Drugs Affecting Lipid Metabolism

      • A. N. Howard

      Pages 77-87

   6. The Fine Structure of Nonatherosclerotic Intimal Thickening, of Developing, and of Regressing Atherosclerotic Lesions at the Bifurcation of the Left Coronary Artery

      • Herbert C. Stary, Jack P. Strong

      Pages 89-108

   7. Apo-Lipoprotein Localization in Human Atherosclerotic Arteries

      • H. F. Hoff, R. L. Jackson, A. M. Gotto Jr.

      Pages 109-120

3. Rabbit Models

   1. Front Matter

      Pages 121-121

      PDF

   2. Rabbits as a Model for the Study of Hyperlipoproteinemia and Atherosclerosis

      • B. Shore, V. Shore

      Pages 123-141

   3. Seasonal Variations in Severity of Experimental Atherosclerosis in Rabbits

      • David Kritchevsky, Shirley A. Tepper, Jon A. Story

      Pages 143-147

   4. Study of Drugs Affecting Cholesterol-Induced Atherosclerosis in Rabbits

      • Y. S. Kwak, K. T. Lee, D. N. Kim

      Pages 149-167

   5. Turnover and Aortic Uptake of Very Low Density Lipoproteins (VLDL) from Hypercholesteremic Rabbits as a Model for Testing Antiatherosclerotic Compounds

      • J. Rodriguez, A. Catapano, G. C. Ghiselli, C. R. Sirtori

      Pages 169-189

   6. Evaluation of the Permeability Parameters (Influx, Efflux and Volume of Distribution) of Arterial Wall for LDL and Other Proteins

      • S. Ghosh, J. N. Finkelstein, D. B. Moss, J. S. Schweppe

      Pages 191-204

   7. Oxygen Diffusion and Atherosclerosis

      • Joseph D. Pool, John L. Gainer, Guy M. Chisolm III

      Pages 205-211

4. Rodent Models

   1. Front Matter

      Pages 213-213

      PDF

   2. High Volume Screening Procedures for Hypobetalipoproteinemic Activity in Rats

      • Paul E. Schurr, John R. Schultz, Charles E. Day

      Pages 215-229

   3. Biological Activity of a Hypobetalipoproteinemic Agent

      • Charles E. Day, Paul E. Schurr, William E. Heyd, Daniel Lednicer

      Pages 231-249

   4. Nonisotopic Method for Estimating Cholesterogenesis in the Rat

      • W. A. Phillips, J. M. Ratchford, J. R. Schultz

      Pages 251-265

   5. Cholesterol Metabolism in Rats Sensitive to High Cholesterol Diet

      • Nozomu Takeuchi, Masami Ito, Yuichi Yamamura

      Pages 267-288

Although atherosclerosis is the leading cause of death in the so-called affluent societies, there is presently no drug in our pharmacologic armamentarium against disease to either prevent or reverse this insidious killer and debilitant of human lives. Because of this void the First Brook Lodge Symposium on Anti­ Atherosclerosis Drug Discovery was convened at Brook Lodge in Augusta, Michigan, August 13-15, 1975. The symposium was sponsored by The Upjohn Company and was international in scope, with investi­ gators attending from such countries as England, Japan, Belgium, and Italy. The symposium focused on the problems associated with the discovery and evaluation of new drugs effective in preventing or reversing atherosclerosis. The thrust of material is centered around animal models useful as tools in the search and evaluation of new drugs. Broadly categorized, the models are nonhuman primates, rabbits, rodents, quail, and tissue culture. The material is a mix of studies on serum lipids and, more importantly, of studies on the artery, irrespective of serum lipid levels. The prevention of arterial lesions, not reduction of serum lipids, is emphasized. A review of all anti-atherosclerotic agents, with the exception of hypolipidemic agents, is included in this volume of the proceedings of the symposium.

• Lipoprotein
• artery
• atherosclerosis
• death
• drug
• drug discovery
• drugs
• evaluation
• lipide
• pharmacology
• prevention
• tissue

• Atherosclerosis Research, The Upjohn Company, Kalamazoo, USA

  Charles E. Day

Policies and ethics